Cordis Unveils Game-Changing Cardiovascular Trial Results Revolutionizing CAD Treatment

Cordis announced groundbreaking findings from the SELUTION DeNovo and SELUTION4ISR trials at TCT 2025, highlighting the potential of SELUTION SLR™ Drug-Eluting Balloon (DEB) as an alternative to traditional drug-eluting stents. The trials met primary endpoints, underscoring SELUTION SLR™ DEB's efficacy in coronary artery disease treatment.

The global cardiovascular company, Cordis, has revealed significant results from the SELUTION DeNovo and SELUTION4ISR trials at the Transcatheter Cardiovascular Therapeutics® 2025 symposium. These trials underscore the efficacy of the SELUTION SLR™ Drug-Eluting Balloon (DEB) as a viable alternative to conventional drug-eluting stents in the treatment of coronary artery disease.

The SELUTION DeNovo trial, the largest randomized Drug-Eluting Balloon study to date, demonstrated that the SELUTION SLR™ DEB approach is non-inferior to traditional stenting in treating de novo lesions. Enrolling over 3,323 patients across 62 international sites, the trial showed promising outcomes, marking a pivotal shift in coronary intervention strategies.

The SELUTION4ISR trial, meanwhile, confirmed the non-inferiority of SELUTION SLR™ DEB over the standard treatment for In-Stent Restenosis, with significant target lesion failure results at 12 months. Cordis continues to spearhead innovation in cardiovascular care, standing at the forefront of transforming percutaneous coronary intervention techniques.

(With inputs from agencies.)